September 2nd 2025
The partnership expands patient access in MENA by localizing biosimilar manufacturing and distribution for gastro, neuro, and dermatology treatments.
August 29th 2025
The acquisition expands tubular glass vial and ampoule capacity, expanding ready-to-use glass packaging capabilities in Europe.
August 26th 2025
August 18th 2025
Bristol Myers Squibb and SystImmune’s iza-bren shows promising efficacy and safety in EGFR-mutant NSCLC after TKI and chemotherapy, backed by data from global and China-based trials.
August 12th 2025
Strand advances targeted mRNA therapies, with Phase I STX-001 solid tumor data presented at the 2025 ASCO Annual Meeting.
Modernization of India’s Pharma Manufacturing Industry: “Leader” or “Laggard”
Guest contributor B.S. Sathya Durga discusses the importance of modernizing India's pharmaceutical manufacturing industry.
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is expected to strengthen its sickle cell disease portfolio.
Sartorius to Acquire Albumedix for £415 Million
Sartorius’ £415 million (US$429 million) acquisition of Albumedix is intended to bolster its portfolio with recombinant albumin-based solutions.
Catalent to Acquire Metrics Contract Services for $475 Million
Catalent will acquire Metrics Contract Services for $475 million to expand high-potent capabilities and oral development and manufacturing capacity.
Sanofi and Innovent Enter Oncology Collaboration
Sanofi and Innovent have entered into a strategic collaboration to accelerate development of oncology medicines and expand their presence in China.
Senate Advances Drug Price Negotiations
Democrats approve curbs for Medicare plans, but not for commercial drug coverage.
The Evolution of Cellular Therapies in a New Clinical Research Environment
The clinical trial research environment has evolved because of specific solutions designed to overcome uncertainty.
Amgen Will Acquire Chemocentryx in $4 Billion Deal
Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).
La Jolla Institute for Immunology Acquires Carterra LSA Platform
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
Ipsen Strikes Deal Worth Up to $1.59 Billion With Marengo Therapeutics
Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.
CRYOPDP Acquires Polar Expres
CRYOPDP is expanding its footprint to Spain with its acquisition of Polar Expres.
Driving Manufacturing Improvements Through Viral Vector Advances
The growth in demand of viral-vector-based gene therapies drives continuous efforts to improve viral vector manufacturing.
Discovery Life Sciences Acquires AllCells
Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.
AstraZeneca to Acquire TeneoTwo in Deal Worth Up to $1.26 Billion
AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.
Cytiva Acquires Chromatography Resins Manufacturing Facility in Muskegon, Michigan
Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.
Royalty Pharma Acquires Royalty Rights to COPD/Asthma Treatment for $1.6 Billion
Royalty Pharma is paying $1.6 billion for the royalty rights to Trelegy Ellipta, a treatment for COPD and asthma.
Vertex to Acquire ViaCyte for $320 Million
Vertex’s $320 million acquisition of ViaCyte will give the company complementary capabilities for its Type 1 diabetes therapy program.
Merck Digital Sciences Studio Supports Early-Stage Startups
Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.
Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA
Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.
IND Applications Face Challenges Early On in Development Cycle
Avoiding roadblocks through strategic planning early on can help facilitate IND application filings.
Development of Bispecific Antibodies Pushes Forward
The recent approvals of bispecific antibodies have opened the gate for the further development of these complex molecules.
Wacker Biotech Expands Germany Site with Construction of New mRNA Competence Center
Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.
Coya Therapeutics Secures Rights to Exosome Engineering Technology from Carnegie Mellon University
Coya Therapeutics has secured intellectual property rights to the research, development, and manufacturing of exosome-polymer hybrids.
VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies
VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.
LG Chem Renews License with Avacta for IND Studies
LG Chem has decided to proceed with IND-enabling studies and has renewed a license with Avacta.
Evolution to a New Clinical Research Environment for Cellular Therapies
Finding specific solutions to overcome uncertainty has led to the evolution of a new clinical trial research environment.
Ipsen Expands Oncology Portfolio with $247 Million Epizyme Acquisition
Ipsen will acquire Epizyme, who recently had their lead medicine Tazverik (tazemetostat) approved by FDA for treatment of relapsed or refractory follicular lymphoma.
ImmunoGen Partners with Oxford BioTherapeutics to Develop Novel ADCs
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
Kindeva Drug Delivery Completes Acquisition of iPharma Labs
Kindeva’s acquisition of iPharma will increase the company’s inhalation formulation outsourcing capabilities.
Aptamer Group Signs Deal with Flip Gene Therapeutics
Aptamer Group has signed a deal with Flip Gene Therapeutics to support the development of inducible gene therapies.